XML 59 R43.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information (Tables)
12 Months Ended
Dec. 31, 2025
Segment Information [Abstract]  
Schedule of Consolidated Statements of Operations

Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s consolidated statements of operations, regularly reviewed by our CODM, include salaries and clinical trials expenses and presented below.

 

   Year ended
December 31,
 
   2025   2024 
         
Operating expenses:        
Research and development salaries and related expenses, other than stock-based compensation   4,493    7,406 
General and administrative salaries and related expenses, other than stock-based compensations   2,707    3,101 
Clinical trials   12,720    12,301 
Research and development stock based compensation   711    600 
General and administrative stock based compensation   1,380    1,248 
Research and development depreciation expenses   2,306    1,486 
General and administrative depreciation expenses   616    317 
Goodwill, IPR&D and Other long-lived asset impairment   13,495    8,084 
Other segment items (*)   3,038    9,980 
Total Operating expenses   41,466    44,523 

 

(*) Other segment items include gain from early lease termination and all remaining costs necessary to operate our business, which primarily include external professional services, rent, insurance and other administrative expenses, and are presented net of grants received.
Schedule of Consolidated Balance Sheets

The Company’s Property and equipment, as well as the Company’s operating lease right-of-use assets recognized on the consolidated balance sheets were located as follows:

 

   As of December 31, 
   2025   2024 
Foreign - Israel   157    6,090 
Domestic - United States   
-
    4,412 
Total   157    10,502